Kardigan, a heart health company modernizing cardiovascular drug development, announced positive Phase 2 data on ataciguat in patients with moderate calcific aortic valve stenosis, presented today in ...
The heart can be compared to a water pump that does not stop working, and the four "gates of the heart" — the mitral, ...
David Battin, MD, cardiologist with the Heart Center at Salina Regional Health Center, has received the Trailblazer Award ...
StockStory.org on MSN
AORT Q3 Deep Dive: AMDS and On-X Outperform, Pipeline and Reimbursement Bolster Outlook
Medical device company Artivion (NYSE:AORT) reported Q3 CY2025 results , with sales up 18.4% year on year to $113.4 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback